What I have: cagrilintide · six weeks · 2–8 °C.
This is a planning question. I know what my options are; I do not know how to weigh them.
What I want is the minimum viable version, which I suspect is smaller than what I would design.
How do I make this decision on evidence rather than on feel?
six weeks is 42 days, and at 2–8 °C the ten-degree rule of thumb makes that roughly 42 refrigerated days of equivalent exposure. 2–8 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. That is short enough that a re-test is a stability study rather than a safety check — worth doing if you will publish the result, hard to justify if you will only reassure yourself. If you do re-test, send it for content as well as purity; the 42 days will have moved one of them further than the other.
Specifically, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemIn practice, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
It helps to be literal here: a statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
If testing multiple vials, state how many you tested and why you chose those vials.
Concretely, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 21 Feb 2026 by zainab_mustafa — added the method parameters
Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.